Kathleen Moore, MD, MS, Stephenson Cancer Center

Kathleen N. Moore, MD, MS, of Stephenson Cancer Center

Kathleen N. Moore, MD, MS, is an associate director of clinical research at the Stephenson Cancer Center, the director of the Oklahoma TSET Phase I Program, and a professor in the Section of Gynecologic Oncology at Oklahoma University (OU) College of Medicine, OU Health.

Articles by Kathleen Moore, MD, MS, Stephenson Cancer Center

Promising Novel Targets for Endometrial Cancer Management

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

Novel Strategies in Development for EC Management

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

Therapy Sequencing Through Multiple Lines of Therapy in EC

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

Impact of Pembrolizumab/Lenvatinib Approval in EC

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

Safety/Efficacy Results From EC Cohort of KEYNOTE-146

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

Rationale for Combination Therapy in Advanced EC

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

GARNET Clinical Trial Regimen in Advanced Disease

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

Second-Line Checkpoint Inhibitor for MSI-H Disease

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

Adjuvant Chemotherapy +/- Radiotherapy: Recent Data

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

Treatment Challenges: Advanced Endometrial Cancer

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

February 4th 2021

Genomic Assessments for Metastatic Disease

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

January 29th 2021

Endometrial Cancer Incidence and Risk Classification

ByKathleen Moore, MD, MS, Stephenson Cancer Center,David M. O'Malley, MD, The Ohio State University

January 29th 2021

Latest Updated Articles

Rationale for Combination Therapy in Advanced EC
February 4th 2021
GARNET Clinical Trial Regimen in Advanced Disease
February 4th 2021
Therapy Sequencing Through Multiple Lines of Therapy in EC
February 4th 2021
Adjuvant Chemotherapy +/- Radiotherapy: Recent Data
February 4th 2021
Safety/Efficacy Results From EC Cohort of KEYNOTE-146
February 4th 2021
Genomic Assessments for Metastatic Disease
January 29th 2021

Trending on OncLive

SurVaxM Cancer Vaccine Shows Clinically Meaningful OS Signal in Newly Diagnosed Glioblastoma

CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer

VS-7375 Elicits Responses in KRAS G12D–Mutated Pancreatic Cancer

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for High-Grade, Papillary-Only BCG-Unresponsive NMIBC

Dr Berdeja on the Potential Role of CELMoDs in Multiple Myeloma Management